人脑的复杂性是研究神经系统疾病和开发有效疗法道路上的巨大挑战。随着人们对大脑理解程度的加 深，传统的细胞培养模型显得过于简化，而动物模型又难以准确反映人类大脑的生物学特性。 为突破这一瓶颈，"迷你大脑"破壁而出。美国麻省理工学院的研究团队开发出一种前所未有的三维人脑 组织平台，并首次在体外系统中完整整合了人脑的6种主要细胞类型。 这是目前最接近真实人脑的体外模型。这一创新模型不仅再现了大脑关键结构与功能特征，还具备高度 可定制性，为阿尔茨海默病等神经退行性疾病的机制研究和药物开发提供了强大工具。 首个含6类细胞的人源三维脑模型 利用这一特性，科学家构建了携带不同载脂蛋白E（ApoE）基因型的"迷你大脑"。ApoE是一种多态性 蛋白，是人体内最重要的脂质转运蛋白，被认为与心血管疾病、阿尔茨海默病等息息相关。 ApoE4则是阿尔茨海默病的最强遗传风险因子。科学家发现，当ApoE4仅存在于星形胶质细胞中，而其 他细胞携带非风险型ApoE3时，miBrains仍表现出阿尔茨海默病相关蛋白——淀粉样蛋白和磷酸化tau蛋 白的积累。这表明，携带ApoE4的星形胶质细胞，就足以驱动关键病理过程。 这种病理变化，依赖于星形胶 ...

Core Viewpoint - Thermo Fisher Scientific (TMO.US) has seen a stock increase of over 2.2%, reaching $539.55, due to its collaboration with OpenAI aimed at enhancing the speed and success rate of drug development [1] Company Summary - Thermo Fisher Scientific is integrating OpenAI APIs into various areas including product development, service delivery, and customer engagement to improve efficiency in drug development [1]

Core Insights - Medpace reported strong Q2 2025 earnings, exceeding both revenue and earnings forecasts, with GAAP revenue of $603.3 million and GAAP EPS of $3.10 [1][2] - The company raised its revenue and net income guidance for FY2025, reflecting confidence in continued operational progress [10][11] Financial Performance - Q2 2025 GAAP revenue grew by 14.2% year-over-year, surpassing estimates by $64.5 million [5] - GAAP EPS increased by 12.7% compared to Q2 2024, from $2.75 to $3.10 [2] - EBITDA (Non-GAAP) rose by 16.2% year-over-year, with an EBITDA margin of 21.6% [2][6] Business Operations - Medpace specializes in clinical trials for pharmaceutical and biotech firms, providing a full suite of services across all phases of clinical development [3] - The company focuses on therapeutic areas such as oncology, cardiology, metabolic diseases, and infectious diseases, enhancing its competitive positioning [4][8] Market Trends - The backlog conversion rate improved to 21.2%, indicating efficient contract-to-revenue conversion [5] - Net new business awards reached $620.5 million, a 12.6% increase year-over-year, resulting in a book-to-bill ratio of 1.03x [5] Cost and Profitability - Selling, general, and administrative expenses increased by 12.5% compared to Q2 2024, attributed to a larger global footprint [7] - GAAP net income margin decreased from 16.7% to 15.0% due to rising expenses [6] Shareholder Returns - The company repurchased 1.75 million shares for $518.5 million, reducing the diluted share count by 9.2% year-over-year [7] Future Outlook - Management raised FY2025 revenue guidance to a range of $2.42 billion to $2.52 billion, with expected GAAP net income of $405 million to $428 million [10] - Key themes to monitor include new bookings, backlog growth, and the impact of rising costs on future margins [11]